{
    "clinical_study": {
        "@rank": "134418", 
        "arm_group": [
            {
                "arm_group_label": "PF-05175157 PIC in fed state", 
                "arm_group_type": "Experimental", 
                "description": "200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal)."
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fed state", 
                "arm_group_type": "Experimental", 
                "description": "200 mg single dose of PF-05175157 administered as tablet formulation  in the fed state (following a standard high fat meal)."
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fed state (repeat)", 
                "arm_group_type": "Experimental", 
                "description": "200 mg single dose of PF-05175157 administered as tablet formulation  in the fed state (following a standard high fat meal)."
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fasted state", 
                "arm_group_type": "Experimental", 
                "description": "200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study in healthy volunteers is to assess the relative bioavailability of\n      PF-05175157 as powder-in-capsule and a tablet formulation and the effect of food on the\n      pharmacokinetics of the tablet formulation."
        }, 
        "brief_title": "A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive\n\n          -  Women must be of non childbearing potential\n\n          -  Body Mass Index (BMI) of 25 to 35 kg/m2; and a total body weight >50 kg (110 lbs)\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal\n             allergies at time of dosing) disease or clinical findings at Screening.\n\n          -  Active ocular disease including infection, glaucoma, seasonal allergies, dry eye\n             symptoms, optic nerve disease or retinal disease.\n\n          -  History of habitual smoking in the past 5 years or history or evidence of habitual\n             use of other (non smoked) tobacco or nicotine-containing products within 3 months of\n             Screening or positive cotinine test at Screening or Day 0"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821079", 
            "org_study_id": "B1731014"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-05175157 PIC in fed state", 
                "description": "Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fed state", 
                "description": "Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fed state (repeat)", 
                "description": "Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-05175157 tablet in fasted state", 
                "description": "Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)", 
                "intervention_name": "PF-05175157", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Single dose", 
            "Relative Bioavailability", 
            "Food effect", 
            "Healthy subjects", 
            "Diabetes Mellitus Type 2"
        ], 
        "lastchanged_date": "May 20, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731014&StudyName=A%20Healthy%20Volunteer%20Study%20To%20Assess%20Relative%20Bioavailability%20Of%20Powder-In-Capsule%20And%20A%20Tablet%20Formulation%20And%20The%20Effect%20Of%20Food%20On%20T"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 72 H after dose"
            }, 
            {
                "measure": "Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)", 
                "safety_issue": "No", 
                "time_frame": "0 to 72 H after dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821079"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0 to 72 H after dose"
            }, 
            {
                "measure": "Time at which maximum plasma concentration is observed (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0 to 72 H after dose"
            }, 
            {
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0 to 72 H after dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}